AbVision, Inc., an innovative biopharmaceutical company, has developed two novel bispecific therapeutic antibody candidates: AVI-525B and AVI-535B, powered by its SpeedyAb™ technology platform of therapeutic antibody.

CD47 is a “don’t eat me” signal that is over expressed on cancer cells and enables cancer cells to escape macrophage phagocytosis. Blocking of CD47 significantly enables tumor cell phagocytosis and activates an ant- tumor T cell response. Anti-CD47 clinical candidates are being evaluated as an anti-cancer therapy both as a mono and combination therapy with good efficacy and safety profiles. Recent data also showed that blockade of CD47 inhibitory signaling greatly enhances innate and adaptive immune responses against viral infection.

The previously developed AVI-105, a monospecific anti-CD47 therapeutic antibody, demonstrated equivalent or better preclinical profiles in comparison to its clinical reference antibody, Magrolimab (http://abvisioninc.com/news-andevents). To further enhance the efficacy and safety of CD47-targeting therapeutics, we are developing a series of antiCD47 bispecific antibodies pairing with other AbVision’s proprietary immune checkpoint inhibitors. The panel of therapeutic bispecific antibody candidates effectively dual-targets two distinct mechanisms of actions on T cells and innate cells for eliciting enhanced anti-tumor activity.

AVI-525B, a bispecific anti-CD47 pairing with a T cell checkpoint inhibitor, induced significantly enhanced anti-tumor effects than individual reference therapeutic antibody. The mice treated with AVI-525B showed an excellent survival rate on a 40 days study period. No significant body weight change was observed after the treatment of AVI-525B (Fig. 1). AVI-535B, a second bispecific anti-CD47 pairing with another T cell checkpoint inhibitor, also demonstrated a superior efficacy and safety profiles compared to the existing monospecific antibody treatment for human liquid tumor (Fig. 2). AVI-525B and AVI-535B are two of the successful examples in our bispecific antibody program. The company is continually developing a series of next generation of bispecific antibodies and further advances the project to the INDenabling stage. Both therapeutic candidates are available for out-licensing and collaborations for downstream development and clinical studies.

About SpeedyAb™

AbVision’s SpeedyAb™ Technology platform provides high-throughput features of antibody preparation for obtaining the therapeutic leads with high affinity and broad diversity (http://abvisioninc.com/technology).

About AbVision

AbVision, Inc. is a biopharmaceutical company with its R&D center in the SF Bay Area. The Company focuses on discovery and development of therapeutic antibodies, vaccines and cell therapy. The Company’s innovative technology platforms provide distinct advantages for antibody discovery, vaccine development and cancer therapies. AbVision aims

to use the novel SpeedyAb™, ImmunoBuster^TM, TsKill™ technology platforms for generating next generation of biotherapeutics in cancer therapy and infectious diseases. Several monoclonal antibodies for cancer therapies and vaccine candidates are available for out-licensing to enable faster downstream development and clinical studies. Please see AbVision website (http://abvisioninc.com) for the details.

For Licensing and Collaborations

Contact AbVision’s Business Development and Licensing Department (BD&L) by email licensing@abvisioninc.com or phone +1-408-493-1822. For more information about AbVision, visit www.abvisioninc.com.